NMS · Biotechnology

LYEL (LYEL) Stock

$12.94 -5.69% NMS: LYEL Healthcare

Valuation

MetricValue
Price$12.94
Market Cap$317.09M
P/E Ratio-1.00
P/B Ratio1.52
P/S Ratio12607.93
EPS (TTM)$-16.06
52-Week High$45.00
52-Week Low$8.46
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-110.48%
ROA-80.59%
ROCE-82.26%
Gross Margin-74.23%
Operating Margin-6189.10%
Net Margin-7948.58%
Debt/Equity0.14
Current Ratio5.33

Annual Financials (USD)

Metric20212022202320242025
Revenue$11.0M$85.0M$0$0$0
Operating Profit$-215.0M$-187.0M$-247.0M$-359.0M$-204.0M
Net Profit$-250.0M$-183.0M$-235.0M$-343.0M$-274.0M
EPS$-1.03$-0.74$-0.93$-1.31$-16.06
Op Margin-2016.7%-220.9%-190006.1%-588122.9%-566038.9%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$1.1B$938.0M$750.0M$491.0M$340.0M
Total Liabilities$198.0M$104.0M$95.0M$108.0M$92.0M
Cash$294.0M$124.0M$146.0M$106.0M$60.0M
Borrowings$68.0M$68.0M$63.0M$59.0M$42.0M

Latest News

B. Riley Initiates Lyell Immunopharma at Buy With $44 Price Target MT Newswires · Jul 22, 2026 Lyell Immunopharma Files for Secondary Offering of Common Shares MT Newswires · Jul 13, 2026 AbCellera Appoints Dr. Lynn Seely to its Board of Directors Business Wire · Jul 6, 2026 Wall Street Analysts Think Lyell Immunopharma (LYEL) Could Surge 176.02%: Read This Before Placing a Bet Zacks · Jul 2, 2026 Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference GlobeNewswire · Jun 25, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-126.0M$-170.0M$-164.0M$-162.0M$-150.0M
Investing Cash Flow$-187.0M$-36.0M$181.0M$122.0M$53.0M
Financing Cash Flow$9.0M$0$0$0$0
Net Cash Flow$153.0M$-170.0M$22.0M$-39.0M$-46.0M
Free Cash Flow$-192.0M$-194.0M$-166.0M$-163.0M$-151.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-34.39%
Quick Ratio7.23
Interest Coverage—
Return 1Y16.29%
Return 3Y-78.77%
Return 5Y-95.83%

Ownership

Insiders Held39.52%
Institutions Held56.86%
Institutions Float Held94.00%
Institutional HolderSharesReport Date
Arch Venture Management, Llc3,247,1622026-03-31
GSK plc1,512,6592026-03-31
Mwg Caph Ltd1,008,1162025-12-31
Foresite Capital Management IV, LLC800,3992026-03-31
Orland Properties Ltd.754,6982026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACIU $2.31 +0.22% -4.04 $234.59M 0.00%
ALDX $1.60 +3.23% -2.77 $96.51M 0.00%
ALLO $1.95 +2.63% -2.17 $673.05M 0.00%
AMRNAmarin Corporation plc $14.58 +0.80% -9.00 $301.45M 0.00%
CABA $2.71 -2.17% -2.23 $441.88M 0.00%

About LYEL

LYEL is led by CEO Lynn Seely, employs 300 people, headquartered in US, publicly traded since 2021.

LYEL stock trades at $12.94 with a market capitalization of $317.09M. The stock is valued at a price-to-earnings (P/E) ratio of -1.00, price-to-book of 1.52, price-to-sales of 12607.93. Over the past 52 weeks the stock has ranged between $8.46 and $45.00, and currently trades 71.2% below its 52-week high.

On profitability, LYEL generates a return on equity (ROE) of -110.48%, return on capital employed of -82.26%, an operating margin of -6189.10%, a net profit margin of -7948.58%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides